REGENXBIO Management
Management criteria checks 2/4
REGENXBIO's CEO is Curran Simpson, appointed in Jul 2024, has a tenure of less than a year. total yearly compensation is $2.95M, comprised of 17.4% salary and 82.6% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $147.91K. The average tenure of the management team and the board of directors is 5.9 years and 7.4 years respectively.
Key information
Curran Simpson
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 17.4% |
| CEO tenure | less than a year |
| CEO ownership | 0.03% |
| Management average tenure | 5.9yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Oct 31Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$239m |
| Jun 30 2024 | n/a | n/a | -US$241m |
| Mar 31 2024 | n/a | n/a | -US$260m |
| Dec 31 2023 | US$3m | US$513k | -US$263m |
| Sep 30 2023 | n/a | n/a | -US$261m |
| Jun 30 2023 | n/a | n/a | -US$274m |
| Mar 31 2023 | n/a | n/a | -US$270m |
| Dec 31 2022 | US$2m | US$475k | -US$280m |
| Sep 30 2022 | n/a | n/a | US$74m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$101m |
| Dec 31 2021 | US$3m | US$448k | US$128m |
| Sep 30 2021 | n/a | n/a | -US$212m |
| Jun 30 2021 | n/a | n/a | -US$145m |
| Mar 31 2021 | n/a | n/a | -US$121m |
| Dec 31 2020 | US$2m | US$428k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$91m |
| Jun 30 2020 | n/a | n/a | -US$135m |
| Mar 31 2020 | n/a | n/a | -US$103m |
| Dec 31 2019 | US$2m | US$382k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$64m |
| Jun 30 2019 | n/a | n/a | -US$49m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$2m | US$371k | US$100m |
| Sep 30 2018 | n/a | n/a | US$80m |
| Jun 30 2018 | n/a | n/a | US$78m |
| Mar 31 2018 | n/a | n/a | US$53m |
| Dec 31 2017 | US$912k | US$361k | -US$73m |
Compensation vs Market: Curran's total compensation ($USD2.95M) is above average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Curran's compensation has increased whilst the company is unprofitable.
CEO
Curran Simpson (62 yo)
less than a year
Tenure
US$2,950,002
Compensation
Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$2.95m | 0.031% $ 147.9k | |
| Executive VP & Chief Scientific Officer | 7.7yrs | US$2.99m | 0.061% $ 289.4k | |
| Advisor | less than a year | US$2.62m | 0.38% $ 1.8m | |
| Executive VP & Chief Medical Officer | 5.6yrs | US$3.31m | 0% $ 0 | |
| Executive VP & CFO | less than a year | no data | no data | |
| Executive VP & Chief Legal Officer | 8.3yrs | US$3.44m | 0.046% $ 219.5k | |
| Chief Communications & People Officer | 7.1yrs | no data | no data | |
| Executive VP of Commercial Strategy & Operations | 6.3yrs | no data | no data |
5.9yrs
Average Tenure
55yo
Average Age
Experienced Management: RGNX's management team is seasoned and experienced (5.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$2.95m | 0.031% $ 147.9k | |
| Independent Director | 9.1yrs | US$339.98k | 0.0061% $ 29.0k | |
| Independent Director | 3.2yrs | US$339.98k | 0.0061% $ 29.0k | |
| Independent Director | 9.5yrs | US$352.48k | 0.013% $ 62.6k | |
| Member of Scientific Advisor | no data | no data | no data | |
| Director | 15.8yrs | US$354.98k | 6.39% $ 30.5m | |
| Member of Scientific Advisor | no data | no data | no data | |
| Independent Director | 6.5yrs | US$327.48k | 0.0061% $ 29.0k | |
| Lead Independent Director | 8.3yrs | US$334.98k | 0.0061% $ 29.0k | |
| Independent Director | 3.2yrs | US$324.98k | 0.0061% $ 29.0k | |
| Chairman | 15.7yrs | US$5.92m | 0.63% $ 3.0m | |
| Independent Director | 2.4yrs | US$329.98k | 0.0040% $ 19.3k |
7.4yrs
Average Tenure
69.5yo
Average Age
Experienced Board: RGNX's board of directors are considered experienced (7.4 years average tenure).